Feature | Robotic Systems | May 05, 2021

Second Generation Robotic PCI System Performs Well Across Spectrum of Lesion Complexity

Multicenter PRECISION GRX Study showed the Siemens Corpath GRX is safe and effective in variety of real-world lesions

The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  Christoper Baker, M.D., Hoag Memorial Hospital using the system. #SCAI21 #SCAI2021

The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  

May 5, 2021 — A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic system had high rates of clinical and technical success across the spectrum of lesion complexity. The multicenter PRECISION GRX Study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting.

This second generation robotic-assisted percutaneous coronary intervention (PCI) system enables robotic guidance of catheters, guidewires and balloons and stent delivery from a lead-lined cockpit across the room from the patient. The system removes the operators from the radiation field and allows them to precisely navigate the wires using a joystick console and eliminates their need to wear lead, or to stand for the procedures. 

The PRECISION GRX study (NCT 03278301) evaluated the safety and efficacy of CorPath GRX in treating a real-world, all-comers population.

This prospective international multicenter registry study enrolled patients with obstructive coronary artery disease (>70% stenosis) with clinical indications for PCI treated with robotic PCI. The co-primary endpoints were clinical success (final TIMI 3 flow, <30% residual stenosis without in-hospital major adverse cardiac event) and technical success (robotic clinical success without the need for unplanned manual assistance/conversion).

The study enrolled 980 patients (65.4 ±11.6 years; 73.5% male; 1,233 lesions), 31.6% with acute coronary syndrome and 68.8% with ACC/AHA type B2/C lesions at 20 centers (Table). Clinical success was achieved in 97.8 % (955/976) of subjects and 98.1% (1,204/1,227) of lesions treated robotically. Device technical success was achieved in 86.5% (848/980) of subjects and 89.2% (1,100/1,223) of lesions treated robotically. Technical success was higher for type A/B1 lesions as compared to type B2/C lesions (94.5% vs 85%, p<0.001). 

The trial also reported on the robotic guide catheter and wire control and the new Rotate on Retract function, which mimics operator hand-wire manipulations in complex lesions and chronic total occlusions (CTOs). Corindus recently introduced several advanced robotic wire movements to more accurately mimic interventional wire manipulation techniques.  Read more about this new technology.

This study was conducted by the following researchers: Ehtisham Mahmud, M.D., FSCAI, The University of California; Jeffrey M. Schussler, M.D., FSCAI, Baylor University Medical Center; William J. Nicholson, M.D., Emory HealthCare; Tejas M. Patel, M.D., FSCAI, Apex Heart Institute, India; William Lombardi, M.D., University of Washington Medical Center; Frances Wood, M.D., WakeMeds; Adam C. Salisbury, M.D., FSCAI, Saint Luke's Mid America Heart Institute; Srini Potluri, M.D., FSCAI, Baylor Scott and White The Heart Hospital — Plano; and Alexandra J. Lansky, M.D., FSCAI, Yale University.


Related Robots in the Cath Lab Content:

VIDEO: Standardizing PCI Through Smart Robotic Procedural Automation

Corindus Launches technIQ 1 Smart Procedural Automation Series for CorPath GRX Cath lab Robotic System

FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions

VIDEO: Corindus CorPath Robotic PCI System For The Cardiac Cath Lab

Corindus CorPath Used in World's First-in-Human Telerobotic Coronary Intervention

14 Ways to Reduce Radiation Exposure in the Cath Lab

Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System

Innovations Driving the Cath Lab Technology of Tomorrow

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

Hoag Performs First Robotic Carotid Artery Stenting on West Coast

Find more news from the SCAI 2021 virtual meeting

Related Content

News | SCAI

June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor ...

Home June 01, 2023
News | SCAI

May 24, 2023 — The largest interventional study focused on pulmonary embolisms highlighted importance of rapid removal ...

Home May 24, 2023
Feature | SCAI | Christine Book

May 23, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) welcomed its 46th President and 2023 ...

Home May 23, 2023
News | SCAI

May 19, 2023 — Findings from a study examining the relationship between marijuana use and peripheral artery disease (PAD ...

Home May 19, 2023
News | SCAI

February 7, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced the second application ...

Home February 07, 2023
News | SCAI

January 18, 2023 — the Society for Cardiovascular Angiography & Interventions (SCAI) announced four recipients of their ...

Home January 18, 2023
News | SCAI

December 8, 2022 — The Society for Cardiovascular Angiography & Interventions (SCAI), a leading nonprofit medical ...

Home December 08, 2022
News | SCAI

May 10, 2022 — After two years of virtual meetings, the Society for Cardiovascular Angiography & Interventions (SCAI) ...

Home May 10, 2022
Feature | SCAI

May 21, 2020 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 21, 2020
News | SCAI

May 17, 2020 – A new study shows that when compared with patients without intermediate left main coronary artery disease ...

Home May 17, 2020
Subscribe Now